Journal of Bodywork and Movement Therapies
Volume 12, Issue 2 , Pages 169-182 , April 2008

Expression of the endocannabinoid system in fibroblasts and myofascial tissues

  • John M. McPartland, M.S., D.O.

      Affiliations

    • Corresponding Author InformationCorresponding author at: 53 Washington Street Extension, Middlebury, VT 05753, USA. Tel.: +18023888304.

Received 7 November 2007 ,Revised 29 December 2007 ,Accepted 8 January 2008.

References 

  1. Abe M, Sogabe Y, Syuto T, Yokoyama Y, Ishikawa O. Evidence that PI3K, Rac, Rho and Rho kinase are involved in basic fibroblast growth factor-stimulated fibroblast—collagen matrix contraction. Journal of Cellular Biochemistry. 2007;102:1290
  2. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nature Neuroscience. 2007;10:870–879
  3. Aguado T, Romero E, Monory K, Palazuelos J, Sendtner M, Marsicano G, et al. The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis. Journal of Biological Chemistry. 2007;282:23892–23898
  4. Ashton JC. Cannabinoids for the treatment of inflammation. Current Opinion in Investigational Drugs. 2007;8:373–384
  5. Ashton JC, Appleton I, Darlington CL, Smith PF. Cannabinoid CB1 receptor protein expression in the rat choroid plexus: a possible involvement of cannabinoids in the regulation of cerebrospinal fluid. Neuroscience Letters. 2004;364:40–42
  6. Bari M, Oddi S, De Simone C, Spagnolo P, Gasperi V, Battista N, et al. Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal cells. Neuropharmacology. 2007;54:45–50
  7. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Molecular Pharmacology. 2003;63:908–914
  8. Berger, A., Crozier, G., Bisogno, T., Cavaliere, P., Innis, S., Di Marzo, V., 2001. Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proceedings of the National Academy of Sciences of the United States of America 98, 6402–6406.
  9. Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urbán GM, et al. Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science. 2007;316:1212–1216
  10. Blechschmidt E. Beginnings of Human Life. Berlin: Springer; 1977;
  11. Crystal JD, Maxwell KW, Hohmann AG. Cannabinoid modulation of sensitivity to time. Behaviour and Brain Research. 2003;144:57–66
  12. Curtis MA, Faull RL, Glass M. A novel population of the progenitor cells expressing cannabinoid receptors in the subependymal layer of the adult normal and Huntington's disease human brain. Journal of Chemical Neuroanatomy. 2006;31:210–215
  13. Degenhardt BF, Darmani NA, Johnson JC, Towns LC, Rhodes DC, Trinh C, et al. Role of osteopathic manipulative treatment in altering pain biomarkers: a pilot study. Journal of the American Osteopathic Association. 2007;107:387–394
  14. Dickson BJ. Molecular mechanisms of axon guidance. Science. 2002;298:1959–1964
  15. Dietrich A, McDaniel WF. Endocannabinoids and exercise. British Journal of Sports Medicine. 2004;38:536–541
  16. Dodd JG, Good MM, Nguyen TL, Grigg AI, Batia LM, Standley PR. In vitro biophysical strain model for understanding mechanisms of osteopathic manipulative treatment. Journal of the American Osteopathic Association. 2006;106:157–166
  17. Dossey L. PEAR Lab and Nonlocal Mind: Why They Matter. New York: Explore; 2007;pp.191–196
  18. Dunnett AJ, Roy D, Stewart A, McPartland JM. The diagnosis of fibromyalgia in women may be influenced by menstrual cycle phase. Journal of Bodywork and Movement Therapies. 2007;11:99–105
  19. Emboden WA. Adaptogens: a new formula for health?. Osteopathic Physician. 1976;73(8):68–73
  20. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54:2838–2843
  21. Food and Drug Administration. FDA Briefing Document: New Drug Application 21-888. Zimulti (rimonabant). Washington, DC: Food and Drug Administration; 2007;Available at: 〈www.fda.gov/ohrms/dockets/AC/07/briefing/2007-4306b1-fda-backgrounder.pdf〉
  22. Fowler CJ. Possible involvement of the endocannabinoid system in the actions of three clinically used drugs. Trends in Pharmacological Science. 2004;25:59–61
  23. Frazer KA, Elnitski L, Church DM, Dubchak I, Hardison RC. Cross-species sequence comparisons: a review of methods and available resources. Genome Research. 2003;13:1–12
  24. In:  Freeman B editors. The Ontogenetic Basis of Human Anatomy, by Erich Blechschmidt. Berkeley, CA: North Atlantic Books; 2004;
  25. Fride E. The endocannabinoid-CB(1) receptor system in pre- and postnatal life. European Journal of Pharmacology. 2004;500:289–297
  26. Galarreta M, Erdelyi F, Szabo G, Hestrin S. Electrical coupling among irregular-spiking GABAergic interneurons expressing cannabinoid receptors. Journal of Neuroscience. 2004;24:9770–9778
  27. Gasperi V, Fezza F, Pasquariello N, Bari M, Oddi S, Agro AF, et al. Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cellular and Molecular Life Sciences. 2007;64:219–229
  28. Gaus K, Le Lay S, Balasubramanian N, Schwartz MA. Integrin-mediated adhesion regulates membrane order. Journal of Cellular Biology. 2006;174:725–734
  29. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004;29:2108–2114
  30. Gokoh M, Kishimoto S, Oka S, Mori M, Waku K, Ishima Y, et al. 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. Biochemical Journal. 2005;386:583–589
  31. Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Research. 2002;954:73–81
  32. Guzman M. Cannabinoids: potential anticancer agents. Nature Reviews Cancer. 2003;3:745–755
  33. Harbach H, Moll B, Boedeker RH, Vigelius-Rauch U, Otto H, Muehling J, et al. Minimal immunoreactive plasma beta-endorphin and decrease of cortisol at standard analgesia or different acupuncture techniques. European Journal of Anaesthesiology. 2007;24:370–376
  34. He F, Song ZH. Molecular and cellular changes induced by the activation of CB2 cannabinoid receptors in trabecular meshwork cells. Molecular Vision. 2007;13:1348–1356
  35. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ, et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology. 2005;30:508–515
  36. Hill MN, Ho WS, Sinopoli KJ, Viau V, Hillard CJ, Gorzalka BB. Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic–pituitary–adrenal axis. Neuropsychopharmacology. 2006;31:2591–2599
  37. Högestatt ED, Jonsson BA, Ermund A, Andersson DA, Bjork H, Alexander JP, et al. Conversion of acetaminophen to the bioactive N-acylphenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. Journal of Biological Chemistry. 2005;280:31405–31412
  38. Hohmann AG, Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience. 1999;92:1171–1175
  39. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacological Reviews. 2002;54:161–202
  40. Ingber D. In search of cellular control: signal transduction in context. Journal of Cellular Biochemistry Supplement. 1998;30–31:232–237
  41. Johnson DR, Stebulis JA, Rossetti RG, Burstein SH, Zurier RB. Suppression of fibroblast metalloproteinases by ajulemic acid, a nonpsychoactive cannabinoid acid. Journal of Cellular Biochemistry. 2007;100:184–190
  42. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nature Reviews Immunology. 2005;5:400–411
  43. Koeberle PD, Bahr M. Growth and guidance cues for regenerating axons: where have they gone?. Journal of Neurobiology. 2004;59:162–180
  44. Langevin HM, Bouffard NA, Badger GJ, Churchill DL, Howe AK. Subcutaneous tissue fibroblast cytoskeletal remodeling induced by acupuncture: evidence for a mechanotransduction-based mechanism. Journal of Cellular Physiology. 2006;207:767–774
  45. Li JJ, Chen RM, Liu L, Wang SY, Yu P, Xie Y, et al. Effects of electroacupuncture on the immunoreactivity of focal cutaneous CB2 receptor positive cells in arthritis rats. Zhen Ci Yan Jiu. 2007;32:9–15
  46. Mancall AC, DiGregorio GJ, Brill CB, Ruch E. The effect of delta-9-tetrahydrocannabinol on rat cerebrospinal fluid. Archives of Neurology. 1985;42:1069–1071
  47. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl). 2002;159:379–387
  48. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, et al. Regulation, function and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. Journal of Clinical Endocrinology and Metabolism. 2006;91:3171–3180
  49. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends in Endocrinology and Metabolism. 2007;18:27–37
  50. Mátyás F, Urbán GM, Watanabe M, Mackie K, Zimmer A, Freund TF, et al. Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology. 2007;54:95–107
  51. Mbvundula EC, Bunning RA, Rainsford KD. Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. Biochemical Pharmacology. 2005;69:635–640
  52. McPartland JM, Guy G. The evolution of Cannabis and coevolution with the cannabinoid receptor—a hypothesis. In:  Guy G,  Robson R,  Strong K,  Whittle B editor. The Medicinal Use of Cannabis. London: Royal Society of Pharmacists; 2004;p. 71–102
  53. McPartland JM, Simons DG. Myofascial trigger points: translating molecular theory into manual therapy. Journal of Manual and Manipulative Therapies. 2007;14:232–239
  54. McPartland JM, Skinner E. The biodynamic model of osteopathy in the cranial field. Explore (NY). 2005;1(1):21–32
  55. McPartland JM, Giuffrida A, King J, Skinner E, Scotter J, Musty RE. Cannabimimetic effects of osteopathic manipulative treatment. Journal of the American Osteopathic Association. 2005;105:283–291
  56. McPartland JM, Matias I, Di Marzo V, Glass M. Evolutionary origins of the endocannabinoid system. Gene. 2006;370:64–74
  57. McPartland JM, Norris RW, Kilpatrick CW. Tempo and mode in the endocannabinoid system. Journal of Molecular Evolution. 2007;65:267–276
  58. Mechoulam R, Fride E, Di Marzo V. Endocannabinoids. European Journal of Pharmacology. 1998;359:1–18
  59. Mense S, Simons DG, Hoheisel U, Quenzer B. Lesions of rat skeletal muscle after local block of acetylcholinesterase and neuromuscular stimulation. Journal of Applied Physiology. 2003;94:2494–2501
  60. Newman SA, Frenz DA, Tomasek JJ, Rabuzzi DD. Matrix-driven translocation of cells and nonliving particles. Science. 1985;228:885–889
  61. Newman Z, Malik P, Wu TY, Ochoa C, Watsa N, Lindgren C. Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction. European Journal of Neuroscience. 2007;25:1619–1630
  62. O’Leary DS, Block RI, Turner BM, Koeppel J, Magnotta VA, Ponto LB. Marijuana alters the human cerebellar clock. Neuroreport. 2003;14:1145–1151
  63. Oliva JM, Uriguen L, Perez-Rial S, Manzanares J. Time course of opioid and cannabinoid gene transcription alterations induced by repeated administration with fluoxetine in the rat brain. Neuropharmacology. 2005;49:618–626
  64. Ortiz S, Oliva JM, Perez-Rial S, Palomo T, Manzanares J. Chronic ethanol consumption regulates cannabinoid CB1 receptor gene expression in selected regions of rat brain. Alcohol and Alcoholism. 2004;39:88–92
  65. Oschman JL. The electromagnetic environment: implications for bodywork: Part 2: Biological effects. Journal of Bodywork and Movement Therapies. 2000;4(2):137–150
  66. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews. 2006;58:389–462
  67. Panagiotis M, Lloyd DH, Pfeiffer D, Stevens K, Auxilia S, Noli C, et al. Veterinary wounds: assessment of the effect of an aliamide-containing topical gel by evaluation of the reduction of wound volume measured by high-resolution ultrasound biomicroscopy. Wounds. 2007;19(5):113–119
  68. Park B, McPartland JM, Glass M. Cannabis, cannabinoids and reproduction. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2004;70:189–197
  69. Pert C. Foreword. In:  Oschman JL editors. Energy Medicine. Edinburgh: Churchill Livingstone; 2000;pp. ix–xi
  70. Pertwee RG. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS Journal. 2005;7:E625–E654
  71. Pevsner J. Leonardo da Vinci's contributions to neuroscience. Trends in Neuroscience. 2002;25:217–220
  72. Raduner S, Majewska A, Chen JZ, Xie XQ, Hamon J, Faller B, et al. Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. Journal of Biological Chemistry. 2006;281:14192–14206
  73. Rimmerman N, Hughes HV, Bradshaw HB, Pazos MX, Mackie K, Prieto AL, et al. Compartmentalization of endocannabinoids into lipid rafts in a dorsal root ganglion cell line. British Journal of Pharmacology. 2007;153:380–389
  74. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nature Medicine. 2007;13:35–37
  75. Russo EB. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuro Endocrinology Letters. 2004;25:31–39
  76. Sánchez-Pastor E, Trujillo X, Huerta M, Andrade F. Effects of cannabinoids on synaptic transmission in the frog neuromuscular junction. Journal of Pharmacology and Experimental Therapeutics. 2007;321(2):439–445
  77. Sarnataro D, Grimaldi C, Pisanti S, Gazzerro P, Laezza C, Zurzolo C, et al. Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cancer cells. FEBS Letters. 2005;579:6343–6349
  78. Scutt A, Williamson EM. Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcified Tissue International. 2007;80:50–59
  79. Shah JP, Phillips TM, Danoff JV, Gerber LH. An in vivo microanalytical technique for measuring the local biochemical milieu of human skeletal muscle. Journal of Applied Physiology. 2005;99:1977–1984
  80. Sioutis J, Roussos N, Manoleas J, Patergianakis N, Charalabidis C, Karantonis G, et al. The memory phenomenon and recurrent musculoskeletal pain. Spinal Cord Journal. 2004;42(Suppl.):S163;Available at: 〈www.iscos.org.uk/abstracts25.html〉
  81. Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A. Exercise activates the endocannabinoid system. Neuroreport. 2003;14:2209–2211
  82. In:  Sutherland WG,  Sutherland AS,  Wales A editor. Contributions of Thought, the Collected Writings of William Garner Sutherland. Kansas City, MO: Sutherland Cranial Teaching Foundation; 1967;
  83. Vann RE, Cook CD, Martin BR, Wiley JL. Cannabimimetic properties of ajulemic acid. Journal of Pharmacology and Experimental Therapeutics. 2007;320:678–686
  84. Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. International Journal of Clinical Practice. 2005;59:291–295
  85. Watanabe S, Doshi M, Hamazaki T. N-3 polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2003;69:51–59
  86. Williams EJ, Walsh FS, Doherty P. The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. Journal of Cellular Biology. 2003;160:481–486
  87. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:5780–5785
  88. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nature Cell Biology. 2004;6:499–506
  89. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Brazilian Journal of Medical and Biological Research. 2006;39:421–429

PII: S1360-8592(08)00007-7

doi: 10.1016/j.jbmt.2008.01.004

Journal of Bodywork and Movement Therapies
Volume 12, Issue 2 , Pages 169-182 , April 2008

Article Tools

* Image Usage & Resolution